Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

What Can We Expect from Celgene's Phase 3 REMARC Trial Data for Non-Hodgkin Lymphoma?

Ticker(s): CELG

Who's the expert?

An oncologist with significant experience treating different types of lymphoma and a familiarity with the REMARC trial.

Interview Questions
Q1.

What is your background in treating lymphoma?

Added By: kcmckee
Q2.

What are your thoughts on the REMARC trial data presented to date?

Added By: kcmckee
Q3.

What factors do you think will potentially help or hurt revlimid make it to market for NHL?

Added By: kcmckee
Q4.

What attributes would make this application of revlimid superior (if at all) to existing drugs like rituximab or other recently approved options e.g. obinutuzumab, idelalisib and ibrutinib?

Added By: kcmckee
Q5.

Where do you see revlimid fitting into the NHL market? 

Added By: kcmckee
Q6.

What do you currently prescribe for NHL and could you see yourself switching to revlimid or some other drug in the near future? What developments are you most excited for in the treatment of NHL?

Added By: kcmckee

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.